Therefore, we collected a cohort of 58 ovarian cancer patients with platinum-sensitive relapsed disease who achieved objective response (partial or complete response [PR or CR]) following the last platinum-based therapy prior to Olaparib Maintenance monotherapy from multiple hospitals in China mainland, which to our knowledge might be the only clinical cohort of PARP inhibitors with both RNA-seq and whole genome sequencing data. The gene discussed is PARP1; the disease is ovarian carcinoma.